| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Novartis AG (VX: NOVN)
NOVN Technical Analysis
4
| As on 20th Jan 2022 NOVN SHARE Price closed @ 81.39 and we RECOMMEND Buy for LONG-TERM with Stoploss of 81.29 & Strong Buy for SHORT-TERM with Stoploss of 78.76 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NOVNSHARE Price
| Open | 81.00 | Change | Price | % |
| High | 81.49 | 1 Day | -0.07 | -0.09 |
| Low | 80.63 | 1 Week | -1.31 | -1.58 |
| Close | 81.39 | 1 Month | 6.54 | 8.74 |
| Volume | 3684028 | 1 Year | 1.00 | 1.24 |
| 52 Week High 86.75 | 52 Week Low 71.11 | ||||
VX Switzerland Most Active Stocks
| CSGN | 9.13 | 0.77% |
| CSGN | 9.13 | 0.77% |
| UBSG | 17.68 | 0.11% |
| UBSG | 17.68 | 0.11% |
| NOVN | 81.39 | -0.09% |
| NOVN | 81.39 | -0.09% |
| ABBN | 34.39 | 1.15% |
| ABBN | 34.39 | 1.15% |
| ARYN | 1.11 | -1.77% |
| ARYN | 1.11 | -1.77% |
VX Switzerland Top Gainers Stocks
VX Switzerland Top Losers Stocks
| NOVN Daily Charts |
NOVN Intraday Charts |
Whats New @ Bazaartrend |
NOVN Free Analysis |
|
|
NOVN Important Levels Intraday
| RESISTANCE | 83.05 |
| RESISTANCE | 82.52 |
| RESISTANCE | 82.19 |
| RESISTANCE | 81.86 |
| SUPPORT | 80.92 |
| SUPPORT | 80.59 |
| SUPPORT | 80.26 |
| SUPPORT | 79.73 |
NOVN Forecast April 2024
| 4th UP Forecast | 104.22 |
| 3rd UP Forecast | 96.9 |
| 2nd UP Forecast | 92.37 |
| 1st UP Forecast | 87.85 |
| 1st DOWN Forecast | 74.93 |
| 2nd DOWN Forecast | 70.41 |
| 3rd DOWN Forecast | 65.88 |
| 4th DOWN Forecast | 58.56 |
NOVN Weekly Forecast
| 4th UP Forecast | 88.62 |
| 3rd UP Forecast | 86.30 |
| 2nd UP Forecast | 84.87 |
| 1st UP Forecast | 83.43 |
| 1st DOWN Forecast | 79.35 |
| 2nd DOWN Forecast | 77.91 |
| 3rd DOWN Forecast | 76.48 |
| 4th DOWN Forecast | 74.16 |
NOVN Forecast2024
| 4th UP Forecast | 113.19 |
| 3rd UP Forecast | 102.99 |
| 2nd UP Forecast | 96.69 |
| 1st UP Forecast | 90.38 |
| 1st DOWN Forecast | 72.4 |
| 2nd DOWN Forecast | 66.09 |
| 3rd DOWN Forecast | 59.79 |
| 4th DOWN Forecast | 49.59 |
Novartis AG ( VX Switzerland Symbol : NOVN )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
NOVN Business Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service